BIOMAT Database Logo BIOMAT Database Logo

Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. 1998

J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
University of Barcelona, Hospital Clinic, Villarroel, Spain.

OBJECTIVE We performed a clinical trial to determine whether postoperative adjuvant chemotherapy with two drugs versus one drug could prolong survival. METHODS From 1985 to 1996, 85 patients with completely resected locally advanced gastric cancer were enrolled. The subjects were randomized into two treatment groups, as follows: mitomycin (MMC) 10 to 20 mg/m2 intravenously (i.v.) on day 1 every 6 weeks plus ftorafur (FT) 500 mg/m2/d for 36 consecutive days; or MMC alone, 10 to 20 mg/m2 i.v. every 6 weeks. All courses were repeated four times. RESULTS After a median follow-up duration of 62 months, the overall 5-year survival rates were 67% for the MMC-FT group versus 44% for the MMC group (P = .04). Subgroup analysis to compare survival curves using the method of Mantel-Cox showed survival rates significantly in favor of the MMC-FT group in the subsets of patients with node-negative disease (P = .01) and those whose disease was stage IB or II (P = .008). CONCLUSIONS Significantly better survival results were observed for MMC-FT versus MMC alone. Subset analysis suggest a strong benefit in patients with node-negative and early-stage resected gastric cancer.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D005743 Gastrectomy Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed) Gastrectomies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer.
December 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
January 2023, American journal of cancer research,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
January 2018, JAMA surgery,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer.
December 2007, The British journal of surgery,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur].
April 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
July 2018, European urology,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Re: Adjuvant Sandwich Chemotherapy plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: A Randomized Phase 2 Trial.
January 2019, The Journal of urology,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer.
June 2017, Anticancer research,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.
February 2015, American journal of clinical oncology,
J J Grau, and J Estapé, and J Fuster, and X Filella, and J Visa, and J Terés, and G Soler, and S Albiol, and J C García-Valdecasas, and L Grande, and J Bombí, and J Bordas, and F Alcobendas
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
January 2024, Nature communications,
Copied contents to your clipboard!